{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06445062",
            "orgStudyIdInfo": {
                "id": "RMC-GI-102"
            },
            "organization": {
                "fullName": "Revolution Medicines, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors",
            "officialTitle": "A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "study-of-ras-on-inhibitors-in-patients-with-gastrointestinal-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-05-24",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-05-15",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-07-15",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-20",
            "studyFirstSubmitQcDate": "2024-05-30",
            "studyFirstPostDateStruct": {
                "date": "2024-06-06",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-30",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-06",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Revolution Medicines, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents.\n\nThe first three subprotocols include the following:\n\nSubprotocol A: RMC-6236 + 5-fluorouracil-based regimens\n\nSubprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6\n\nSubprotocol C: RMC-6236 + gemcitabine + nab-paclitaxel",
            "detailedDescription": "The platform study design allows combinations of RAS(ON) inhibitors with other anticancer agents to be evaluated in patients with RAS-mutated solid tumors with a focus on GI cancers.\n\nThis is an open-label platform study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard of Care (SOC) or with novel agents, and to define the Recommended Phase 2 Dose and Schedule (RP2DS). Enrollment of patients with RAS mutations will be specified in each subprotocol.\n\nSubprotocol A is an open-label, multicenter study of RMC-6236 in combination with 5-fluorouracil-based regimens in patients with unresectable or metastatic colorectal cancer or metastatic pancreatic ductal adenocarcinoma. Subprotocol B is an open-label, multicenter study of RMC-6236 in combination with cetuximab with or without mFOLFOX6 in patients with unresectable or metastatic colorectal cancer or metastatic pancreatic ductal adenocarcinoma. Subprotocol C is an open-label, multicenter study of RMC-6236 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. Each subprotocol consists of two parts: Part 1 - Dose Exploration and Part 2 - Dose Expansion."
        },
        "conditionsModule": {
            "conditions": [
                "Colorectal Cancer",
                "CRC",
                "Pancreatic Ductal Adenocarcinoma",
                "PDAC",
                "Gastrointestinal Cancer",
                "Metastatic Pancreatic Ductal Adenocarcinoma"
            ],
            "keywords": [
                "CRC",
                "PDAC",
                "RAS Mutation",
                "KRAS G12X",
                "Colorectal Cancer",
                "Pancreatic Cancer",
                "Pancreatic Ductal Carcinoma",
                "KRAS Q61 Mutation",
                "KRAS G12 Mutation",
                "RAS Wild-type"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 406,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Subprotocol A: RAS-mutated unresectable or metastatic CRC or metastatic PDAC",
                    "type": "EXPERIMENTAL",
                    "description": "RMC-6236 (QD) and Bevacizumab with 5-fluorouracil-based regimens",
                    "interventionNames": [
                        "Drug: RMC-6236",
                        "Drug: mFOLFOX6 regimen",
                        "Drug: bevacizumab",
                        "Drug: mFOLFIRINOX regimen"
                    ]
                },
                {
                    "label": "Subprotocol B: RAS-mutated unresectable or metastatic CRC or metastatic PDAC",
                    "type": "EXPERIMENTAL",
                    "description": "RMC-6236 (QD) and Cetuximab with or without mFOLFOX6",
                    "interventionNames": [
                        "Drug: RMC-6236",
                        "Drug: mFOLFOX6 regimen",
                        "Drug: cetuximab"
                    ]
                },
                {
                    "label": "Subprotocol C: metastatic PDAC",
                    "type": "EXPERIMENTAL",
                    "description": "RMC-6236 (QD) and Gemcitabine with Nab-paclitaxel",
                    "interventionNames": [
                        "Drug: RMC-6236",
                        "Drug: gemcitabine",
                        "Drug: nab-paclitaxel"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "RMC-6236",
                    "description": "Oral tablet",
                    "armGroupLabels": [
                        "Subprotocol A: RAS-mutated unresectable or metastatic CRC or metastatic PDAC",
                        "Subprotocol B: RAS-mutated unresectable or metastatic CRC or metastatic PDAC",
                        "Subprotocol C: metastatic PDAC"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "mFOLFOX6 regimen",
                    "description": "IV infusion",
                    "armGroupLabels": [
                        "Subprotocol A: RAS-mutated unresectable or metastatic CRC or metastatic PDAC",
                        "Subprotocol B: RAS-mutated unresectable or metastatic CRC or metastatic PDAC"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "bevacizumab",
                    "description": "IV infusion",
                    "armGroupLabels": [
                        "Subprotocol A: RAS-mutated unresectable or metastatic CRC or metastatic PDAC"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "mFOLFIRINOX regimen",
                    "description": "IV infusion",
                    "armGroupLabels": [
                        "Subprotocol A: RAS-mutated unresectable or metastatic CRC or metastatic PDAC"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "cetuximab",
                    "description": "IV infusion",
                    "armGroupLabels": [
                        "Subprotocol B: RAS-mutated unresectable or metastatic CRC or metastatic PDAC"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "gemcitabine",
                    "description": "IV infusion",
                    "armGroupLabels": [
                        "Subprotocol C: metastatic PDAC"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "nab-paclitaxel",
                    "description": "IV infusion",
                    "armGroupLabels": [
                        "Subprotocol C: metastatic PDAC"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Adverse events",
                    "description": "Evaluate the safety and tolerability in the study population characterized by incidence, abnormal laboratory assessments, severity, and seriousness of adverse events in relation to the study treatment.",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Dose limiting toxicities",
                    "description": "Number of participants with dose limiting toxicities",
                    "timeFrame": "28 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Pharmacokinetics of RMC-6236",
                    "description": "Blood concentration of RMC-6236 over time",
                    "timeFrame": "21 weeks"
                },
                {
                    "measure": "ORR",
                    "description": "Overall Response Rate per RECIST v1.1",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "DOR",
                    "description": "Duration of Response per RECIST v1.1",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "DCR",
                    "description": "Incidence of Response per RECIST v1.1",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "TTR",
                    "description": "Time to Response per RECIST v1.1",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "PFS",
                    "description": "Progression Free Survival per RECIST v1.1",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "OS",
                    "description": "Overall Survival",
                    "timeFrame": "Up to 3 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nAll Patients (unless otherwise noted):\n\n* \u2265 18 years of age\n* ECOG PS is 0 to 1\n* Adequate organ function as outlined by the study\n* Must have pathologically documented, pancreatic carcinoma with documented metastatic disease or RAS-mutated, histologically or cytologically confirmed colorectal adenocarcinoma with documented unresectable or metastatic disease (Subprotocol A and B)\n* Must have pathologically documented, poorly differentiated pancreatic carcinoma with documented metastatic disease (Subprotocol C) -\n\nExclusion Criteria:\n\nAll Patients:\n\n* Primary central nervous system (CNS) tumors\n* Impaired gastrointestinal (GI) function that may significantly alter the absorption of RMC drugs\n* Major surgery within 28 days of first dose\n\nOther inclusion/exclusion criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Revolution Medicines",
                    "role": "CONTACT",
                    "phone": "650-779-2300",
                    "email": "CT-inquiries@RevMed.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Study Director",
                    "affiliation": "Revolution Medicines",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "NEXT Oncology Dallas",
                    "status": "RECRUITING",
                    "city": "Irving",
                    "state": "Texas",
                    "zip": "75039",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.81402,
                        "lon": -96.94889
                    }
                },
                {
                    "facility": "Virginia Cancer Specialists",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22314",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000015179",
                    "term": "Colorectal Neoplasms"
                },
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                },
                {
                    "id": "D000005770",
                    "term": "Gastrointestinal Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007414",
                    "term": "Intestinal Neoplasms"
                },
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000005767",
                    "term": "Gastrointestinal Diseases"
                },
                {
                    "id": "D000003108",
                    "term": "Colonic Diseases"
                },
                {
                    "id": "D000007410",
                    "term": "Intestinal Diseases"
                },
                {
                    "id": "D000012002",
                    "term": "Rectal Diseases"
                },
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "asFound": "Adenocarcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M13110",
                    "name": "Pancreatic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M22725",
                    "name": "Carcinoma, Pancreatic Ductal",
                    "relevance": "LOW"
                },
                {
                    "id": "M25356",
                    "name": "Carcinoma, Ductal",
                    "relevance": "LOW"
                },
                {
                    "id": "M17890",
                    "name": "Colorectal Neoplasms",
                    "asFound": "Colorectal Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "asFound": "Gastrointestinal Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10448",
                    "name": "Intestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6336",
                    "name": "Colonic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10444",
                    "name": "Intestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14844",
                    "name": "Rectal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "T4387",
                    "name": "Pancreatic Cancer",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000017239",
                    "term": "Paclitaxel"
                },
                {
                    "id": "D000068258",
                    "term": "Bevacizumab"
                },
                {
                    "id": "D000093542",
                    "term": "Gemcitabine"
                },
                {
                    "id": "D000068818",
                    "term": "Cetuximab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000972",
                    "term": "Antineoplastic Agents, Phytogenic"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000050257",
                    "term": "Tubulin Modulators"
                },
                {
                    "id": "D000050256",
                    "term": "Antimitotic Agents"
                },
                {
                    "id": "D000050258",
                    "term": "Mitosis Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000020533",
                    "term": "Angiogenesis Inhibitors"
                },
                {
                    "id": "D000043924",
                    "term": "Angiogenesis Modulating Agents"
                },
                {
                    "id": "D000006133",
                    "term": "Growth Substances"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000006131",
                    "term": "Growth Inhibitors"
                },
                {
                    "id": "D000000964",
                    "term": "Antimetabolites, Antineoplastic"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M19537",
                    "name": "Paclitaxel",
                    "asFound": "Sessions",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2985",
                    "name": "Gemcitabine",
                    "asFound": "Mg/kg",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8600",
                    "name": "Fluorouracil",
                    "relevance": "LOW"
                },
                {
                    "id": "M231",
                    "name": "Albumin-Bound Paclitaxel",
                    "relevance": "LOW"
                },
                {
                    "id": "M246",
                    "name": "Bevacizumab",
                    "asFound": "Non-",
                    "relevance": "HIGH"
                },
                {
                    "id": "M315",
                    "name": "Cetuximab",
                    "asFound": "Physician",
                    "relevance": "HIGH"
                },
                {
                    "id": "M26197",
                    "name": "Tubulin Modulators",
                    "relevance": "LOW"
                },
                {
                    "id": "M26196",
                    "name": "Antimitotic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M22318",
                    "name": "Angiogenesis Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M9231",
                    "name": "Growth Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}